Two cases of hyperprolactinaemia and one case of depression caused by oxetorone are described. These rare side effects are probably related to the pharrnacological properties of the drug.
Get full access to this article
View all access options for this article.
References
1.
AussemsGBauthierJChailletFColotMVan DammeMCharlierR.Recherche dans la série des benzofurannes: profil pharmacologique de I'oxétorone.
Thérapie1971;
26:
11–35,
11–54
2.
RossiEDe PascaleANegriniPZanolMFrigerioA.Oxetorone metabolism in vitro.
J Chromatogr1978;
152:
228–33
3.
0. DufresneJJ.Double-blind study of oxetorone in patients with migraine or migrainous headache.
Praxis1978;
67:
1148–52
0. HenryPSeilheanA.Utilisation thérapeutique du L6257 dans les céphalées migraineuses.
Semaine Hôp. Paris1975;
51:
387–9
6.
PradalierAVincentDBeaulieuPHRouxelMHyperprolactinémie induite par I'lndoramine.
Presse Médicale 1996 à paraître
7.
LancranjanIDel PozoEPiccioliniED'AntonaNGenazzaniAR.Effect of two serotonin antagonists on prolactin release induced by breast stimulation in postpartum women.
Hormone Res1979;
10:
14–9
8.
DolecekRJanstovaV.Long-term effect of pizotifen treatment on growth hormone levels of underweight children, including those with anorexia nervosa.
Pharmatherapeutica1985;
4
(2):
81–7
9.
BegaudBEvreuxJCJouglardJLagierG.Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France.
Thérapie1985;
40:
111–8
10.
BenakisASugnauxFPlessasCBouvierC.Pharmacokinetics of oxetorone, an anti-migraine drug in man.
Experientia1985;
41:
818
